Ovarian cancer breakthrough:
New treatment 'found to dramatically shrink tumours'
Experts said the results of the early-phase study were "exciting" and "promising" after patients who had exhausted all other treatment options showed an impressive response.
The drug, known as ONX-0801 in the phase 1 clinical trial, was tested in 15 women with advanced ovarian cancer as part of a wider trial run by the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust in London.
The aim was to test its safety, but the results were so good that researchers are keen to move the drug to the next stage of research as soon as possible.
"The beauty of this particular drug is that it is targeted to the cancer cell.
"This means there are fewer side-effects, making it a kinder treatment for ovarian cancer patients.
Time to get a move on Novogen!!!! There's some pretty stiff competition out there.
NRT Price at posting:
4.0¢ Sentiment: Buy Disclosure: Held
